FDA Approves Liquid CaroSpir in Heart Disease

August 9, 2017

CMP Pharma received FDA approval for CaroSpir (spironolactone oral suspension), an oral liquid dosage form of the diuretic. Until now, patients with difficulty swallowing tablets were prescribed a pharmacy compounded liquid form of spironolactone.

CaroSpir is indicated for treatment of certain classes of heart failure to manage edema and is usually administered in conjunction with other therapies. It is also indicated as an add-on therapy for hypertension.

The company expects to introduce CaroSpir in the fourth quarter of this year.

View today's stories